BPC-157 has 100-plus studies, nearly all from one Zagreb group

Who produced most of the BPC-157 research?

Most of BPC-157's more than 100 published studies come from one University of Zagreb group, led by Predrag Sikiric and using peptide synthesized in its own lab ^[1]⁠^[2]⁠^[3]. Nearly every review cited below on BPC-157's proposed mechanisms and effects is written or co-written by Sikiric, often with overlapping coauthors, across two decades ^[1]⁠^[2]⁠^[3]⁠^[4]⁠^[5].

The concentration reflects the structure of the field, not a quirk of which papers get cited. A large share of the BPC-157 literature consists of the same group publishing new reviews that restate and extend its own earlier animal work. Each new review inflates the apparent size of the evidence base without adding an independent test of it.

How is BPC-157 proposed to work?

The Zagreb group proposes that BPC-157 acts through nitric oxide signaling, recruitment of blood vessels around injured tissue, and stabilization of cell membranes in stressed tissue ^[2]⁠^[3]. The group describes BPC-157 as a stable fragment related to a protective protein in gastric juice. Its authors extend a concept they call "cytoprotection" from the stomach lining to other tissues, under the label "organoprotection" ^[2]⁠^[3].

Reviews in this line describe effects across gut, skin, tendon, muscle, and vascular tissue in animal models. They frame those effects as a general stress-coping and tissue-maintenance mechanism rather than a single-organ drug effect ^[1]⁠^[4].

The framework is coherent and mechanistically plausible as its originating lab describes it. None of the studies cited below shows unaffiliated researchers confirming it at the mechanistic level.

How strong is the evidence for BPC-157?

On a standard evidence-grading scale, BPC-157's animal-model mechanism data from a single, non-replicated source sit far below controlled human trials and below even modest independent animal replication. The reviews cited below, each originating from or heavily involving the Zagreb group, summarize the group's own primary rodent and animal-model data across gastrointestinal, vascular, and musculoskeletal tissue ^[1]⁠^[2]⁠^[3]⁠^[4]⁠^[5]⁠^[7]⁠^[8]. That is a legitimate research program with a long publication history. It is not an independently replicated one.

Paper count does not change the grade. When ten labs replicate a finding, a reader can start trusting the finding rather than the lab. When one lab produces a finding, restates it, and reviews it repeatedly, the paper count grows but the number of independent checks on the result does not. Evidence-grading frameworks are built to catch that distinction, not the raw number.

Only independent replication moves BPC-157 up the scale, and that has not happened at meaningful scale. Some orthopedic and sports-medicine literature published outside the Zagreb group has raised the same concern about a lack of independent confirmation, so the critique is not one skeptic's reading of the papers.

Did BPC-157's human trial publish its results?

BPC-157's Phase II trial has no independently published, peer-reviewed results report; among the papers cited below, the trial appears only inside the Zagreb group's own reviews ^[6]⁠^[7]⁠^[8]. Several of those reviews reference a Phase II clinical trial for inflammatory bowel disease, under research designations including PL 10, PLD-116, and PL 14736. They describe it as safe, without side effects, and without a lethal dose established in toxicology testing ^[6]⁠^[7]⁠^[8].

Those characterizations come from the same research group that ran the underlying work. No independently published trial report makes the primary data available for outside scrutiny.

A completed human trial described only secondhand, inside reviews from the group that ran it, is a different category of evidence from a trial report published on its own, with methods and results a separate reviewer can evaluate. Until the gap between "referenced as completed" and "published with results" closes, no human safety or efficacy claim from this trial rests on a report outsiders can check. A separate review covers what human BPC-157 studies exist.

Where do BPC-157 dosing protocols come from?

BPC-157 dosing protocols circulate in forums and vendor material without a traceable source, and none comes from a published human trial. Those protocols commonly cite subcutaneous doses in the low hundreds of micrograms, often 250 to 500 mcg, injected near an injury site.

None of the studies cited below reports a human dose-finding study, a human safety trial with published results, or a human efficacy trial outcome that supports a specific number. Doses repeated online at that level of precision are extrapolations, not established doses, and no trial established them as safe or effective. The origins of local BPC-157 injection protocols are traced in a separate analysis.

Does commercial BPC-157 match the peptide used in the studies?

No published data show that commercial BPC-157 matches the peptide the Zagreb group characterized in its own lab. The animal data describe a specific synthesized peptide under specific study conditions.

No published study addresses whether peptide manufactured and sold outside a research or pharmaceutical supply chain matches that material in sequence integrity, purity, or stability. Whether a given commercial product is chemically the same thing remains unanswered.

What is still unknown about BPC-157?

Independent replication of BPC-157's core tissue-repair and mechanism findings by unaffiliated labs is scarce, and that scarcity, not an absence of research, is the evidentiary problem. The open questions:

• Human outcomes. No published controlled trial has established human dose-response, human safety over any meaningful duration, or human efficacy for musculoskeletal recovery.
• Rodent models. Whether findings from rodent tendon, gut, and vascular models generalize to human injury physiology at all remains untested outside the Zagreb group's framework. A separate analysis examines how far BPC-157 animal findings translate to human use.
• Product identity. The literature does not address whether any specific commercial product corresponds to the material used in the underlying studies.

None of this proves BPC-157 is inert or unsafe. The claims resting on "over a hundred studies" have not yet been tested the way science tests claims it trusts: by someone else, in a different lab, getting the same answer.